Skip to main content
    T

    TherapeuticsMD Inc (TXMD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.91
    +0.10 (+5.52%)

    Market Cap: $20.95M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    TherapeuticsMD Inc (TXMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    TherapeuticsMD (TXMD) has a market cap of $20.95M and an enterprise value of $10.50M. It holds $10.45M more cash than debt, 49.87% of its market cap. Revenue grew 33.94% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 49.87% below the market cap, as cash exceeds debt.

    Market Cap$20.95M
    Enterprise Value$10.50M
    Latest price (Nov 17, 2026)$1.91

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 0.18% a year over 2 years.

    Shares Outstanding11.57M
    Shares Change (YoY)0.00%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+0.18%

    Valuation Ratios

    Sales and book value multiples are 5.9x and 0.8x. Its year-end P/S ranged from 1.3x to 74.2x from 2016 to 2025.

    P/S Ratio5.9x
    P/B Ratio0.8x
    P/TBV Ratio0.9x
    P/OCF Ratio6.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 6.3x EBITDA.

    EV / Earnings86.1x
    EV / Sales2.8x
    EV / EBITDA6.3x
    EV / EBIT13.8x

    Price Statistics

    The stock is down 2.55% over 52 weeks and trades 2.55% below its 50-day average.

    Beta (1Y)0.28
    52-Week Change-2.55%
    1-Month Change+2.69%
    3-Month Change-5.91%
    6-Month Change-6.37%
    5-Year Change-95.05%
    10-Year Change-99.37%
    Total Return (1Y)-2.55%
    Total Return (3Y CAGR)-5.59%
    Total Return (5Y CAGR)-42.06%
    Return vs SPY (1Y)+12.47%
    Max Drawdown (1Y)-38.99%
    Max Drawdown (3Y)-75.58%
    Sharpe Ratio (1Y)0.35
    Correlation with SPY (1Y)0.06
    50-Day Average$1.96
    200-Day Average$2.08
    52-Week Range$1.43 to $2.95
    RSI (14 Days)54.5
    Average Volume (20 Days)17.84K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.32x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.32x
    Quick Ratio3.32x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 0.44% and return on assets is 0.32% over the last 12 months.

    Return on Equity (ROE)0.44%
    Return on Assets (ROA)0.32%
    Return on Capital Employed (ROCE)2.33%
    ROA (5Y Average)-1.76%
    ROIC (5Y Average)-2.34%
    Asset Turnover0.10x

    Taxes

    Income tax took 17.02% of pretax income over the last 12 months.

    Income Tax (TTM)$32.00K
    Effective Tax Rate17.02%

    Scores

    TXMD has an Altman Z-Score of -33.29, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-33.29
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $3.75M over the last 12 months.

    Revenue$3.75M
    Revenue Growth (YoY)+33.94%
    Gross Profit$3.75M
    Operating Income-$3.98M
    Pretax Income$188.00K
    Net Income$122.00K
    EBITDA$1.85M
    EBIT$762.00K

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.82% of the $37.93M in total assets.

    Cash and Equivalents$10.45M
    Total Debt$0
    Net Cash$10.45M
    Net Cash Per Share$0.90
    Working Capital$12.17M
    Shareholder Equity$27.62M
    Book Value Per Share$2.39
    Tangible Book Value$24.16M
    Tangible Book Per Share$2.09
    Total Assets$37.93M
    Total Liabilities$10.31M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$3.37M
    FCF Per Share$0.29
    Depreciation and Amortization$1.09M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -106.28%.

    Gross Margin100.00%
    Operating Margin-106.28%
    Pretax Margin5.02%
    Net Margin3.26%
    EBITDA Margin49.37%
    EBIT Margin20.35%
    Gross Margin (5Y Average)88.70%

    Growth

    Revenue fell 64.91% a year over 3 years, and EPS 81.74% a year.

    Revenue Growth (3Y CAGR)-64.91%
    Revenue Growth (5Y CAGR)-45.84%
    EPS Growth (3Y CAGR)-81.74%
    FCF Growth (3Y CAGR)-35.16%
    Book Value Per Share Growth (2Y CAGR)-4.36%
    Tangible Book Per Share Growth (2Y CAGR)-0.32%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-50 reverse split on May 9, 2022.

    Last Split DateMay 9, 2022
    Split TypeReverse split
    Split Ratio1:50

    Peer Position

    Against 6 similar companies, TXMD has the highest P/S.

    P/S Ratio5.9x vs 1.6x median
    Revenue Growth (Trailing 4 Quarters, YoY)+33.94% vs -7.46% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TXMD

    What is TXMD's market cap?

    TherapeuticsMD has a market cap of $20.95M. Its enterprise value, which adds debt and subtracts cash, is $10.50M.

    How many shares of TXMD are outstanding?

    TherapeuticsMD has 11.57M shares outstanding. The count is up 0.00% from a year earlier.

    Does TXMD pay a dividend?

    No. TherapeuticsMD does not pay a dividend.

    How much debt does TXMD have?

    TherapeuticsMD has $0 of total debt and $10.45M of cash and equivalents, a net cash position of $10.45M.